Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$7.31M Buy
+205,000
New +$6.48M ﹤0.01% 1844
2023
Q2
– Sell
-100
Closed -$3.78K – 5628
2023
Q1
$3.78K Buy
+100
New +$3.84K ﹤0.01% 4999

Other funds holding GMAB

Citigroup's GMAB Position: Q3 2026 in Review

Citigroup reduced its Genmab (GMAB) stake by 12% in Q3 2026, selling an estimated $104K and leaving 24,245 shares worth $865K. The position accounts for ﹤0.01% of the portfolio, ranked #3428.

Citigroup first reported a position in GMAB in Q3 2019 and has held it in 29 quarters since. The position peaked at $3.82M in Q4 2020. 333 funds tracked by Wall St. Rank hold GMAB as of Q3 2026.

  • Citigroup held 24,245 shares of Genmab worth $865K as of Q3 2026.
  • Citigroup sold 3,286 Genmab shares in Q3 2026, an estimated $104K.
  • Genmab made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #3428 holding.
  • Citigroup first reported a position in Genmab in Q3 2019 and has held it in 29 quarters since.
  • Citigroup's Genmab position peaked at $3.82M in Q4 2020.
  • 333 funds tracked by Wall St. Rank held Genmab as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.